Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California.
| Revenue (Most Recent Fiscal Year) | $110.49M |
| Net Income (Most Recent Fiscal Year) | $-232.62M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 4.09 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.92 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -122.54% |
| Net Margin (Trailing 12 Months) | -121.52% |
| Return on Equity (Trailing 12 Months) | -25.75% |
| Return on Assets (Trailing 12 Months) | -18.19% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.34 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.34 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $8.70 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.41 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.58 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.40 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 71.32M |
| Free Float | 67.93M |
| Market Capitalization | $572.01M |
| Average Volume (Last 20 Days) | 0.76M |
| Beta (Past 60 Months) | 0.89 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.76% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |